Taiwan Covid Vaccine Packaging Market Size & Outlook, 2026-2034
Taiwan Covid Vaccine Packaging Market Insights
- As highlighted in Packaging Market Insights analysis, the Taiwan Covid Vaccine Packaging Market, worth USD 40.39 Million in 2025, is forecasted to achieve USD 61.34 Million by 2034.
- The Taiwan market is anticipated to grow at a CAGR of 4.78% during the period 2026–2034.
- By 2025, Glass Vials represented the largest share of the Product Type market size.
- Secondary Packaging is expected to remain the key growth driver within Product Type, registering the fastest CAGR during the forecast period.
Source: PIAnalysis Company Publications, Primary Interviews.
Other Key Findings
- Taiwan contributed 1.48% to the global Covid Vaccine Packaging Market size in 2025.
- By 2034, United States is forecasted to remain the largest global market for Covid Vaccine Packaging Market.
- In Asia Pacific, China is projected to capture the leading share of market size by 2034.
- Among Asia Pacific markets, South Korea is expected to post the fastest growth, reaching USD 52.5 Million by 2034.
Report Summary
| Report Scope | Details |
|---|---|
| Base Year for Study | 2025 |
| Study Period | 2022-2034 |
| Historical Period | 2022-2024 |
| Forecast Period | 2026-2034 |
| Market Size In 2025 | USD 40.39 Million |
| Market Size In 2034 | USD 61.34 Million |
| Largest segment | Glass Vials |
| Units | Revenue in USD Million |
| CAGR | 4.78% (2026-2034) |
| Segmnetation Covered | |
| Product Type |
|
| Application |
|
| Distribution Channel |
|
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends |
Taiwan Covid Vaccine Packaging Market Product Type 2026-2034 (USD Million)
| Product Type | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Glass Vials | XX.x | XX.x | XX.x | 18.19 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Prefilled Syringes | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Secondary Packaging | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: PIAnalysis Company Publications, Primary Interviews.
Taiwan Covid Vaccine Packaging Market Application 2026-2034 (USD Million)
| Application | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| mRNA Vaccines | XX.x | XX.x | XX.x | 18.18 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Viral Vector Vaccines | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Protein Subunit Vaccines | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: PIAnalysis Company Publications, Primary Interviews.
Taiwan Covid Vaccine Packaging Market Distribution Channel 2026-2034 (USD Million)
| Distribution Channel | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Direct Supply to Pharmaceutical Companies | XX.x | XX.x | XX.x | 17.32 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Medical & Pharmaceutical Distributors | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Government Procurement | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Hospital & Healthcare Networks | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Contract Packaging Organizations | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: PIAnalysis Company Publications, Primary Interviews.